ASCO preview: How Gilead, Pfizer, AstraZeneca-Daiichi breast cancer data may—or may not—change treatment practice The top 20 drugs by worldwide sales in 2021 GSK strikes $3.3B Affinivax buyout to MAP out challenge to Pfizer's blockbuster pneumococcal vaccine Encompass Health sets July 1 target for its home health, hospice spinoff Roche's Evrysdi ramps up SMA rivalry with Novartis and Biogen thanks to FDA nod in newborns Abbott's slimmed-down FreeStyle Libre glucose sensor notches FDA nod RhoVac's prostate cancer vaccine phase 2 failure forces biotech to cut costs Bristol Myers' Opdivo fights Keytruda again with dual FDA nods in esophageal cancer After Axsome’s migraine med rejection, phase 3 data keeps hope alive for depression drug Aduhelm price cut, limited coverage leads CMS to lower Medicare premiums in 2023 Altoida finds first chief medical officer in Alzheimer's expert hailing from Biogen, Roche CVS Health rolls out virtual primary care service Featured Story | By Angus Liu Breast cancer data from Gilead Sciences’ Trodelvy, Pfizer’s Ibrance and AstraZeneca and Daiichi Sankyo’s Enhertu, to be presented at ASCO this weekend, could shake up breast cancer treatment. We talked to Debu Tripathy, M.D., chair of breast medical oncology at the MD Anderson Cancer Center, to preview those studies. read more |
| |
|---|
|
|
| Biotech got the world back on track. Now, we’re getting back together, and what happens next is Limitless. #BIO2022 |
Top Stories By Kevin Dunleavy While the global sales rankings of Big Pharma's superstar drugs naturally feature the biggest names in the business, several new meds popped up on the list this year because of the coronavirus. Pfizer's COVID-19 vaccine displaced AbbVie's Humira at the top slot, which the immunology drug had held for nearly a decade. read more By Nick Paul Taylor GSK is betting big to reenergize its fight for a share of the pneumococcal vaccine market, agreeing to pay $2.1 billion upfront to acquire Affinivax for a challenger to Pfizer’s blockbuster Prevnar franchise. read more By Dave Muoio Although the deal is still subject to "various conditions," the new publicly traded entity would consist of 252 home health and 99 hospice locations. read more By Kevin Dunleavy Babies that have spinal muscular atrophy now have an at-home treatment option that can help extend their lives. The FDA’s approval of Roche’s Evrysdi opens the oral drug up for infants younger than 2 months old. read more By Andrea Park Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. read more By James Waldron RhoVac’s attempt to develop the first antigen vaccine for prostate cancer has ended in a phase 2 trial failure and forced the Swedish biotech to initiate cost-cutting measures. RV001, also known as onilcamotide, failed to significantly prevent or delay the progression of prostrate cancer. read more By Angus Liu Bristol Myers Squibb’s Opdivo and Merck & Co.’s Keyturda have been duking it out for years across various tumor types. Now, BMS has scored a duo of FDA nods to level the playing field in esophageal cancer. read more By Gabrielle Masson Positive phase 3 trial results have maintained momentum for Axsome Therapeutics' convoluted depression drug application, less than a month after the FDA rejected the company's migraine treatment. read more By Dave Muoio While a mid-year redetermination was deemed unfeasible, HHS Secretary Xavier Becerra said Medicare's Aduhelm cost savings would be passed on to enrollees via lower rates in 2023. read more By Andrea Park As Altoida’s Alzheimer’s disease screening platform inches closer to FDA clearance, the company is bulking up its clinical team. And to lead the way, it's chosen someone who's worked in Alzheimer's at two major drugmakers. read more By Heather Landi Retail drugstore giant CVS is rolling out a virtual care service that gives consumers access to primary care, on-demand care, chronic condition management and mental health services. read more |
